These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 30171175

  • 1. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
    Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.
    Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
    [Abstract] [Full Text] [Related]

  • 2. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Funazo T, Tsuji T, Ozasa H, Furugaki K, Yoshimura Y, Oguri T, Ajimizu H, Yasuda Y, Nomizo T, Sakamori Y, Yoshida H, Kim YH, Hirai T.
    Mol Cancer Ther; 2020 Jun; 19(6):1320-1327. PubMed ID: 32217741
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M, Altavilla G, Rosell R.
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [Abstract] [Full Text] [Related]

  • 7. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S.
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H, Lin C, Peng T, Hu C, Lu C, Li L, Wang Y, Han R, Feng M, Sun F, He Y.
    Cell Death Dis; 2020 Feb 10; 11(2):111. PubMed ID: 32041944
    [Abstract] [Full Text] [Related]

  • 13. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 10; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V, Ou SH.
    Expert Opin Drug Saf; 2017 Apr 10; 16(4):509-514. PubMed ID: 28276856
    [Abstract] [Full Text] [Related]

  • 16. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 10; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 17. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G.
    Lung Cancer; 2020 Aug 10; 146():78-85. PubMed ID: 32521388
    [Abstract] [Full Text] [Related]

  • 18. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
    Srinivasamaharaj S, Salame BK, Rios-Perez J, Kloecker G, Perez CA.
    Expert Rev Anticancer Ther; 2016 Dec 10; 16(12):1227-1233. PubMed ID: 27744726
    [Abstract] [Full Text] [Related]

  • 19. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K.
    J Thorac Oncol; 2019 Nov 10; 14(11):2009-2018. PubMed ID: 31374369
    [Abstract] [Full Text] [Related]

  • 20. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 10; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.